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Abstract
Anorexia nervosa (AN) is a serious, potentially life-threatening disorder characterized by severe 
weight loss, dysregulated eating, and often excessive exercise. While psychiatric illnesses such as 
depression are associated with increased levels of pro-inflammatory mediators, evidence for such 
disturbances in patients with AN has been less clear. To elucidate further immune responses in 
AN, we assayed a panel of cytokines and chemokines in the blood of patients undergoing inpatient 
treatment, testing the hypothesis that metabolic disturbances in this disease would lead to a pattern 
of immune disturbances distinct from that of other psychiatric diseases. For this purpose, we 
evaluated patients by the Beck Depression Inventory-II (BDI-II) and the Eating Disorders 
Examination-Questionnaire and assessed cytokines and chemokines by enzyme-linked 
immunosorbent assays. Patients reported a moderate level of depression (mean BDI-II = 22.6) but 
exhibited few immunologic abnormalities of the kind associated with major depressive disorder 
[e.g., increased interleukin (IL)-6]; RANTES showed the most frequent elevations and was 
increased in 4 of the patients studied. Together, these findings suggest that features of AN such as 
loss of adipose tissue and excessive exercise may attenuate cytokine production and thus modulate 
the experience of illness that impacts on core features of disease.
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AN is a serious, potentially life-threatening psychiatric illness that affects ~1% of the 
population. AN disproportionately afflicts females, and is associated with severe weight 
loss, dysregulated eating, distorted body image, and, often, excessive exercise [1-3]. AN 
carries substantial morbidity and mortality as well as personal, familial, and societal costs. 
Nevertheless, patients affected appear to value the ill state and can make extensive efforts to 
achieve and maintain the starvation that characterizes the illness. Given the clinical features 
of AN, treatment is uncertain and current approaches to therapy carry significant costs 
despite limited efficacy [4-6]. Medications targeting the core symptoms of the disorder 
currently are not available [7-9]. Elucidating the pathogenesis of AN and identifying 
biomarkers are therefore essential for developing more effective interventions.
AN presents a very complex biological setting that encompasses biochemical, metabolic, 
and sensory abnormalities [10-17]. Importantly, changes in visceral experience occur 
prominently in the ill state (e.g., reduced pain sensitivity, reduced detection of visceral 
changes such as heart beat), with findings that differ from alterations in experience 
accompanying food restriction that occurs independently of AN [18,19]. Biological 
alterations that regularly occur during starvation, combined with unique features of the ill 
state of AN, may help to explain why the ill state appears to be so reinforcing for patients.
A potentially important but understudied aspect of AN is the effect of this disorder on the 
immune system. Data from existing studies are conflicting and, while some studies suggest a 
pro-inflammatory state, others indicate few abnormalities [20-30]. In contrast, depression 
and schizophrenia, among other psychiatric diseases, show abundant cytokine disturbances 
and define pro-inflammatory states that co-occur with the experience of mental illness 
[31-35]. The lack of consistent evidence of such a relationship in AN suggests that AN may 
involve a unique interplay between nervous and immune systems and dissociation of 
expected cytokine abnormalities from mood and affect.
The lack of more decisive evidence for cytokine disturbances in AN is notable, particularly 
given that the severe loss of fat in AN would be expected to have important effects on 
immunity. As now recognized, adipose tissue produces many bioactive substances, 
including pro-inflammatory cytokines, such as tumor necrosis factor-α (TNFα) and 
interleukin (IL)-6 [36-39]. In addition to their immunological and metabolic effects, these 
cytokines could play a role in the initiation and maintenance of psychiatric manifestations 
such as disturbances in mood and affect. Notably, in addition to extreme dietary restriction 
with subsequent loss of fat mass, AN can be characterized by engagement in a determined 
excessive exercise routine. Extensive exercise may be relevant to the overall state of the 
immune system in AN since muscle cells, when undergoing contraction, can also produce 
cytokines, known as myokines [40-41]. Of the myokines, IL-6 may have anti-inflammatory 
action at least locally although systemically it can lead to immune activation. Because of 
extensive exercise, the production of myokines could increase in patients and, depending on 
the array of these mediators produced, attenuate inflammation [42-45].
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Since immune mediators can drive metabolic and nervous system disturbances, a focus on 
their role in AN is conceptually and practically important as it suggests potential 
interventions with immunomodulatory agents; such agents could interrupt an injurious cycle 
of metabolic and psychological disturbance. To characterize immune system changes in AN 
and assess any abnormalities present in other psychiatric disorders, we analyzed a panel of 
immune chemokines and cytokines in a cohort of well-characterized AN patients undergoing 
inpatient treatment. Results of these studies indicate that patients with AN show few 
abnormalities in the expression of cytokines and chemokines. As such, patients with AN 




Participants were 30 females ages 15 to 45 who met DSM-IV criteria for AN (any subtype), 
who were admitted for inpatient treatment at the University of North Carolina Center of 
Excellence for Eating Disorders. Participants were assessed at the time of admission, 
typically at <75% ideal body weight (IBW). For participants who were unable to complete 
the assessment at admission, testing occurred within 1 week of admission with one 
exception (participant ID = 16). Prior to the assessment, participants completed a semi-
structured screening interview designed specifically for this investigation to assess recent 
illness, health history and current medications that could affect cytokine levels. This 
investigation was approved by the Biomedical Institutional Review Board at the University 
of North Carolina at Chapel Hill and all participants provided informed consent.
Blood sampling was unsuccessful in 5 participants, who were therefore omitted from the 
analyses. From the remaining 25 participants, we were unable to assess the full battery of 
psychological or immunological measures on all patients related in part to availability of 
material and patient-related issues.
2.2. Measures
2.2.1. Body Composition—Height and weight were assessed using a stadiometer and a 
calibrated digital scale. Body mass index (BMI) was calculated as weight (kg)/height (m2). 
Body fat percent was determined by dual x-ray absorptiometry (DXA).
2.2.2. Eating Disorder and Psychopathology Assessment
2.2.2.1. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition 
Module H (SCID-I/P) [46]: The SCID-I/P, a well-studied and frequently employed semi-
structured interview for Axis I disorders was used to assesses eating pathology.
2.2.2.2. The Eating Disorders Examination-Questionnaire (EDE-Q) [47]: The EDE-Q is 
a 38-item self-report measure of eating disorder psychopathology over the past 28 days. The 
EDE-Q is based on the EDE [48], a valid and reliable investigator-administered interview 
for assessing current eating disorder symptoms. The EDE-Q yields a global score and four 
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subscale scores (restraint, eating concerns, weight concerns, and shape concerns), each with 
a range of 0 to 6.
2.2.2.3. Beck Depression Inventory-II (BDI-II) [49]: The BDI is a 21-item self-report 
questionnaire that is used to assess the severity of current depressive symptoms. Each 
answer is scored on a 4-point scale (0 to 3), with total scores indicating minimal (0-13), mild 
(14-19), moderate (20-28), and severe (29-63) depression.
2.2.2.4. Spielberger State-Trait Anxiety Inventory (STAI) [50]: The STAI is a 40-item 
self-report questionnaire that assesses both state (current, event-related) and trait 
(characterological) anxiety using two 20-item scales. In this study, the STAI was used to 
assess state anxiety. Participants completed a 20-item self-report questionnaire based on a 4-
point scale ranging from 1 (“not at all”) to 4 (“very much”). Example items include 
statements such as, “I am calm”, “I am worried”. Low, median, and high scores indicate 
mild, moderate, and severe forms of anxiety, respectively. A score > 40 is considered high.
2.3. Laboratory
A venous blood sample was obtained from each participant and analyzed for complete blood 
count as well as a comprehensive metabolic panel to assess current kidney and liver function 
and electrolyte and acid/base balance. Additional blood samples were frozen at -80°C, 
stored, and later assayed in batch to measure levels of cytokines.
Immune assays (R&D Systems, Minneapolis, MN, quantitative ELISA) included high-
sensitivity interleukin (IL) 6 and 8 (IL-6, IL-8), IL-1 receptor antagonist (IL1-ra), C-reactive 
protein (CRP), tumor necrosis factor-alpha (TNF-α) and soluble TNF receptor (sTNFR75), 
and monocyte chemotactic protein-1 (MCP-1). sTNFR75 provides another index of the 
function of TNF-α. CRP was assessed as a general measure of inflammation and acute phase 
reactant production. Assays were performed at the Cytokine Analysis Facility of the 
Bioanalytical Core Laboratory at the University of North Carolina at Chapel Hill (IL-6, 
CRP, TNF-a, sTNFR75) and University Hospital of Geneva, Switzerland (IL-8, IL1-Ra, 
MCP-1, RANTES).
For some determinants, IL-8, IL-1Ra, MCP-1 and CCL5/RANTES were measured by a 
commercially available multiplex beads immunoassay, based on the Luminex platform 
(Fluorokine MAP Multiplex Human Cytokine Panel, R&D Systems, Minneapolis, USA) 
according to supplier’s instructions.
2.4 Statistical Analysis
The analyses were mainly descriptive in nature. In addition, exploratory analyses included 
Pearson’s correlations examining relations between and among psychological and 
immunological measures. Given the exploratory nature of this study, we did not adjust the p 
value (alpha = 0.05) for multiple comparisons.
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Table 1 provides demographic, psychological, and immunological data on each of the 25 
study participants. Abnormally high laboratory values are highlighted in bold. Participants 
ranged in age from 19 to 57 years. Consistent with a primary diagnosis of AN, participants’ 
BMI ranged from 13.4 to 18.8 kg/m2 and most reported elevated levels of eating disorder 
psychopathology, depression, and anxiety. Seventeen individuals completed the EDE-Q, 
with global scores ranging from 0.6 to 5.7. Eleven of the 17 individuals (65%) had global 
EDE-Q scores greater than one standard deviation above the normative mean for women 
ages 18-49 [51], suggesting clinically significant pathology.
BDI-II scores ranged from 5 to 49. Two patients reported minimal depression, 6 each 
reported mild or moderate depression, and 4 reported severe depression. STAI scores ranged 
from 20 to 79. Five patients scored < 40; 8 scored between 40 and 59; and 8 scored ≥ 60; 
thus, 76% (16 of 21) patients reported high levels of state anxiety. Body fat percent ranged 
from 5.9% to 20.2%. The highest BMI and body fat percent were observed in participant 16, 
who underwent testing more than 1 week after renourishment began. Table 2 presents the 
descriptive statistics for these measures in the group as a whole.
As results of these experiments indicate, the levels of cytokines measured were almost all 
within the normal range. Among the patients, 1 showed an elevation of TNF-α while 2 
showed an elevation of IL-6. For the chemokines, MCP-1 showed values within the normal 
range whereas levels of RANTES were elevated in 4 patients. These patients did not have 
abnormalities in others of the cytokines and chemokines tested. Of the cytokines measured, 
IL-6 is commonly viewed as the prototype of a myokine.
3.2 Exploratory Analyses
Scores on the psychological measures were strongly correlated with each other (r range 0.61 
to 0.71, p range 0.02 to 0.004). Only one significant correlation was noted between the 
psychological and immunological measures, with the global EDE-Q score being negatively 
associated with TNF-α (r = − 0.48, p < 0.05). Correlations among immunological markers 
revealed strong positive associations between RANTES and IL-8 (r = 0.73, p < 0.0004) and 
MCP-1 (r = 0.62, p < 0.002).
Table 3 displays the psychological measures in the participants with abnormally high 
(>84000) versus normal RANTES (<84000) level. The two groups appear similar in their 
levels of psychological distress; however, the number of patients is too small to draw 
conclusions. Together, these studies support prior studies indicating few cytokine 
abnormalities in patients with AN.
4. Discussion
Patients with AN who had been admitted to an inpatient unit for a program for weight 
restoration showed little evidence of immune system abnormality as evidenced by assays of 
cytokines and chemokines. Of analytes measured, RANTES was elevated in 4 patients while 
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IL-6 was elevated in two; only one patient had an elevated in TNF-α. Together, these 
findings suggest that, despite the many potential physical and psychological triggers to 
immune disturbance in AN, a surprising degree of immune system regulation is maintained 
even in severely ill patients.
Previous studies on cytokine disturbances in AN have yielded conflicting results. Pomeroy 
et al. [23] reported elevations of IL-6 and TGF-β in patients with AN during periods of 
starvation although these levels returned to normal with re-feeding. As in our study, these 
investigators failed to show elevations in TNF-α. Using quantitative PCR to assess cytokine 
mRNA in peripheral blood cells, Kahl et al. [29] showed increases in levels of TNF-α and 
IL-6 during admission to the hospital; TNF-α mRNA levels remained abnormal with re-
feeding, however. Other evidence of immune system activation was found in a study 
indicating increased nitric oxide (NO) production by patients with AN but not in those with 
bulimia nervosa as indicated by levels of nitrites [52].
A variety of factors could explain the differences in findings across studies. These factors 
relate to assay methodology (i.e., blood levels vs. cell-based assays); the features of patients 
studied; and clinical setting (i.e., inpatient vs. outpatient). Differences in criteria for inpatient 
admission across centers could affect the severity of illness of patients studied and therefore 
the extent abnormalities observed. The demographic features of our patients, however, 
suggest that our clinical sample is representative of individuals undergoing inpatient weight 
restoration. Moreover, our results are internally consistent since we analyzed several 
different cytokines yielding similar results.
Among cytokines and chemokines measured, RANTES showed elevations in 4 patients. 
RANTES was originally cloned on the basis of its expression in T cells and subsequently 
renamed as CCL5 [53]. While RANTES has chemokine activity, it may act more broadly 
and impact diseases ranging from HIV infection to malignancy. Like other cytokines and 
chemokines, CLL5 may act as a neuromodulator and contribute to the symptomatology of 
those patients with elevated levels [54-56]. Prior studies have suggested increased RANTES 
levels in several psychiatric diseases [57]. Among the 4 patients in our studies, we did not 
see any major differences in the psychological measures tested.
The absence of elevation of IL-6 is notable in view of its designation as a myokine, a 
cytokine produced in response to muscle contraction. While IL-6 can be produced during 
exercise, the extent of elevation may vary depending on the type and intensity of exercise; 
the condition of the individual undergoing exercise; and the time of sampling [40,42,58]. 
Furthermore, IL-6 may act locally and mediate communication between muscle and adipose 
tissue; in this situation, IL-6 may display anti-inflammatory activity although, when acting 
systemically, it also can drive inflammation and induce the acute phase response [40,41,43]. 
The lack of evidence of significant elevations of IL-6 in this study population therefore does 
not exclude a role of IL-6 in modulating the immune system in AN.
Our study has a number of strengths. We used sensitive immunoassays to assess an array of 
cytokines and chemokines that correspond to various elements of the immune system, with 
CRP protein providing a general measure of immune system activation. In addition, we 
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simultaneously determined psychological measures that reflect various dimensions of AN 
and associated conditions such as depression. Our study has limitations, however. The 
analysis involves a limited number of patients who had been hospitalized for their condition 
and, while we assessed nutritional status and psychological features, we did not measure 
exercise in a quantifiable way. Another limitation relates to a comparison of laboratory 
values to population norms rather than a control population matched for age and sex; we 
also did not have a cohort of patients with depression for direct comparison. Nevertheless, 
our results are very consistent with those in the literature and indicate the absence of 
evidence of inflammation in patients with AN despite the presence of eating disorder 
pathology and related depression and anxiety.
As shown in many studies, AN represents a very unusual biological setting that differs from 
more usual forms of malnutrition with respect to such findings as susceptibility to infection 
[59-61]. Furthermore, many patients with AN remain physically very active, with excessive 
exercise an important feature of the condition [44,45,62,63]. Because of the systemic 
immune effects of exercise, the predicted inflammatory consequences of tissue damage from 
malnutrition may not occur [64-66]. Thus, despite factors (i.e., psychosocial stress) that 
could drive inflammation, patients with AN may have strong counter-regulation secondary 
to their nutritional state, lack of adipose tissue, heightened production of glucocorticoids, 
and/or excessive exercise. The setting of AN therefore represents an important contrast to 
other psychiatric disorders where cytokine production may depend on adipose tissue. 
Furthermore, in other conditions, excessive exercise may not occur, with depression, for 
example, more commonly associated with decreased physical inactivity.
Our findings may be relevant to the putative effects of self-starvation on hallmark 
psychological features of AN such as lack of awareness of patients of the seriousness of the 
illness. As suggested in many studies, self-starvation may represent a strategy to dull an 
internal experience of dysphoria, anxiety, or stress-proneness in susceptible individuals 
[67-69]. To the extent that psychological stress may drive the production of inflammatory 
mediators, our findings are consistent with a hypothesis that features of AN (i.e., starvation, 
exercise) may attenuate aberrant immune responses expected in psychiatric illness. In the 
absence of these responses, patients with AN may not experience illness in a typical way 
and therefore fail to exhibit classic illness behavior (e.g., lack of energy, decreased physical 
activity, pain behaviors) that occurs in other psychiatric conditions.
A lack of illness experience could also contribute to the perplexing symptom that has been 
referred to as “denial of illness” and is now considered to be a failure to recognize the 
seriousness of the illness. Rather than denying or failing to recognize their illness, patients 
with AN may actually not experience illness as typically conceptualized, thereby 
contributing to their common unwillingness to undergo treatment. In fact, patients with AN 
often report feeling markedly less well upon re-nourishment, a time that can be associated 
with changes in steroid hormones, for example [70,71]. Although these symptoms are 
typically explained psychologically as a fear of weight gain, our model would suggest that 
an increase in adipose tissue (an important source of pro-inflammatory mediators during re-
feeding) could “reignite” aberrant immune responses, intensifying an experience of illness 
which had been suppressed by starvation and excessive physical activity. This model clearly 
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contains speculative elements and requires further study, including a longitudinal design to 
document changes throughout the course of illness and not just during the acutely low-
weight state. These studies are in progress and hopefully will provide new insights into 
interplay between the immune system on psychological features of AN.
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Table 2
Variable N Mean (SD) Range Normal Rangea
IL-1RA (pg/mL) 23 247.5 (78.8) 129.2 – 417.9 20 – 880
IL-6 (pg/mL) 21 0.85 (1.36) 0.00 – 6.40 < 1.50
IL-8 (pg/mL) 19 2.29 (0.91) 1.12 – 4.18 < 90
TNFα (pg/mL) 25 1.36 (0.89) 0.65 – 4.62 < 4.00
sR_TNF75 (ng.mL) 23 1.15 (0.25) 0.74 – 1.65 0 – 5
CRP (pg/mL) 25 873047.5 (1680450.7) 26861.9 – 7030199.5 .
MCP_1 (pg/mL) 23 69.5 (21.2) 32.2 – 117.0 50 – 260
RANTES (pg/mL) 23 38696.5 (59193.8) 2294.6 – 235468.1 1200 – 84000
a
Values are laboratory-specific rather than population “norms”
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Table 3
Psych Summary Descriptive Data by RANTES Group
Variable Abnormal RANTES (> 84000) Normal RANTES (≤ 84000)
Global EDE-Q scorea 4.0 (2.5) 4.0 (1.8)
Restraintb 3.1 (3.2) 3.5 (2.2)
Eating Concernb 4.1 (2.7) 3.5 (1.8)
Shape Concerna 4.6 (1.9) 4.7 (1.6)
Weight Concerna 4.4 (2.3) 4.0 (2.0)
BDIc 31.0 (14.7) 20.8 (11.7)
STAId 47.3 (5.1) 54.0 (17.9)
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